“The label change implemented by FDA is reflective of both the extensive data on contrast agents and the well characterized and stable safety profile of DEFINITY, which has been used to perform more ...
NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH) (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, ...
BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow ® disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback